Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer
June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body.
Study Shows Sharp Decline in Cancer Screenings During First COVID-19 Surge
January 15, 2021 — In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses, researchers at Dana-Farber/Brigham and…
Quantib Receives FDA Clearance for First-to-Market Prostate Solution
October 21, 2020 — Quantib, a market leader in artificial intelligence solutions for radiology, today announced that it received FDA clearance for its…
Benefits Manager Policy Disrupts Patient-physician Decision Making for Breast and Prostate Cancer Radiation Treatments
October 2, 2020 — Radiation oncologists expressed serious concerns about a new private insurance coverage policy that could undermine patient-centered care for two of the most common cancers in the United States.
First U.S. Study Shows Promising Outcomes for High-intensity Focused Ultrasound for Prostate Cancer
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the high-intensity focused ultrasound (HIFU) technology has gained…

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced presentations on Axumin (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting

News | PET Imaging

Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and 18F-Fluciclovine at ASTRO21

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

October 19, 2021

Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.

News | Prostate Cancer

Metastatic Prostate Cancer Comes in Two Forms, Which Could Guide Treatment

September 24, 2021 — Scientists have identified two subtypes of metastatic prostate cancer that respond differently to ...

September 24, 2021

Paige Prostate, is the first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.

News | Digital Pathology

FDA Authorizes Software That Can Help Identify Prostate Cancer

September 22, 2021 — The U.S. Food and Drug Administration authorized marketing of software to assist medical ...

September 22, 2021

Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals

News | Radiopharmaceuticals and Tracers

Blue Earth Diagnostics Supports Timely Consideration and Passage of the FIND Act of 2021 by U.S. Congress

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

September 17, 2021

Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus’ prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, to enable real-time therapeutic guidance of biology-guided radiotherapy (BgRT) in prostate cancer using the RefleXion X1 platform.

News | PET Imaging

Lantheus and RefleXion Announce Collaboration with Potential to Improve Future Prostate Cancer Treatment

September 13, 2021 — Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and ...

September 13, 2021

Researchers at Karolinska Institutet in Sweden recently reported that magnetic resonance imaging (MRI) could reduce overdiagnoses and thereby improve prostate cancer screening.

News | Prostate Cancer

MRI Can Cut Overdiagnoses in Prostate-cancer Screening by Half

August 13, 2021 — Researchers at Karolinska Institutet in Sweden recently reported that magnetic resonance imaging (MRI) ...

August 13, 2021

The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R. 4479, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021” by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).

News | Nuclear Imaging

Council on Radionuclides and Radiopharmaceuticals Supports the FIND Act of 2021

August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient ...

August 04, 2021

Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

News | Prostate Cancer

New AI Tech for Early Detection of Prostate Cancer

July 19, 2021 — Prostate cancer is the most diagnosed cancer and a leading cause of death by cancer in Australian men ...

July 19, 2021

Most countries have not introduced nationwide prostate cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half.

News | Prostate Cancer

MRI Can Cut Over-diagnoses in Prostate Cancer Screening by Half

July 12, 2021 — Most countries have not introduced nationwide prostate cancer screening, as current methods result in ...

July 12, 2021

The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

News | PET Imaging

FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate ...

June 28, 2021

A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.

News | Prostate Cancer

PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen ...

June 21, 2021

#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

News | Prostate Cancer

Decrease in Prostate Cancer Diagnoses Due to Pandemic

April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer ...

April 30, 2021

A new study led by Ivan Martinez—associate professor in the WVU School of Medicine and Cancer Institute—found a link between a family of RNAs, the Y chromosome, and radiation sensitivity in male lung-cancer patients

News | Radiation Therapy

Loss of Y chromosome, RNA Tied to Radiation Resistance in Male Lung-cancer Patients

March 23, 2021 — The science behind the COVID-19 vaccine has the potential to do more than prevent cases of COVID-19 ...

March 23, 2021

A national screening program targeted at those men who are genetically pre-disposed to prostate cancer, and involving a blood test and magnetic resonance imaging (MRI) scan before an invasive biopsy, could prevent one in six prostate cancer deaths and significantly reduce over-diagnosis, finds a new study led by UCL researchers.

News | Prostate Cancer

Targeted Screening for Prostate Cancer Could Prevent One in Six Deaths

March 15, 2021 — A national screening program targeted at those men who are genetically pre-disposed to prostate cancer ...

March 15, 2021

Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.

Feature | Treatment Planning | By Melinda Taschetta-Millane

Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and ...

March 05, 2021

Immunotherapy-based precision medicine clinical trials being developed

News | Prostate Cancer

Why Black Men's Prostate Cancer May be More Responsive to Immunotherapy

February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from ...

February 16, 2021

The Milton and Caroll Petrie Department of Urology at Mount Sinai has received a $3.8 million donation from philanthropist Robert F. Smith to launch the Robert F. Smith Mobile MRI Unit in partnership with the Mount Sinai Health System to support prostate health in the Black community.

News | Prostate Cancer

Mount Sinai Receives $3.8 Million Gift to Launch Mobile MRI Unit to Support Prostate Health in the Black Community

February 12, 2021 — The Milton and Caroll Petrie Department of Urology at Mount Sinai has received a $3.8 million ...

February 12, 2021

Phase III clinical trial of men with a clinical suspicion of prostate cancer finds MRI with targeted biopsies to be more accurate at diagnosis and less intrusive than current standard

News | Magnetic Resonance Imaging (MRI)

Using MRI for Prostate Cancer Diagnosis Equals or Beats Current Standard

February 8, 2021 — The results of a Phase III randomized clinical trial have shown that when it comes to detecting ...

February 08, 2021

News | Prostate Cancer

Ultrasound Technique Treats Prostate Cancer with Minimal Side Effects

February 5, 2021 — A technique that delivers high-intensity focused ultrasound to targeted tissue under MRI guidance ...

February 05, 2021

An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost, as shown by a large-scale study initiated by UMC Utrecht in collaboration with the Netherlands Cancer Institute, UZ Leuven and Radboudumc.

News | Prostate Cancer

Radiation Boost Lowers Risk of Prostate Cancer Recurrence

January 25, 2021 — An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects ...

January 25, 2021